Bone Therapeutics SA (BOTHE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bone Therapeutics SA (BOTHE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8198
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bone Therapeutics SA (Bone Therapeutics) is a cell therapy company that develops autologous and allogeneic cell therapy products. The company offers pipeline products such as PREOB, an autologous osteoblastic cell therapy product used for the treatment of osteonecrosis and non-union fractures; and ALLOB, an allogeneic osteoblastic cell therapy product, for delayed-union fractures, spinal fusion procedures, and frevision spinal fusion. Bone Therapeutics conducts preclinical research on next generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications. The company conducts clinical studies for treatment of delayed-union fractures and spinal fusion. Bone Therapeutics is headquartered in Gosselies, Belgium.

Bone Therapeutics SA (BOTHE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bone Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bone Therapeutics SA, Medical Devices Deals, 2012 to YTD 2018 10
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Bone Therapeutics Raises US$8 Million In Series D Financing Round 12
Partnerships 13
Bone Therapeutics to Enter into Agreement with Cellthera Pharm 13
Bone Therapeutics Extends Agreement with Kasios 14
Licensing Agreements 15
Asahi Kasei Enters into Licensing Agreement with Bone Therapeutics 15
Bone Therapeutics Enters into Licensing Agreement with Enrico Bastianelli 16
Enrico Bastianelli Enters into Licensing Agreement with Bone Therapeutics 17
Bone Therapeutics Enters into Licensing Agreement with Enrico Bastianelli for BONE-011 18
Equity Offering 19
Bone Therapeutics Withdraws Private Placement of Shares 19
Bone Therapeutics Raises USD38 Million in IPO 21
Debt Offering 23
Bone Therapeutics Raises USD24.1 Million in Private Placement of Bonds 23
Bone Therapeutics SA – Key Competitors 24
Bone Therapeutics SA – Key Employees 25
Bone Therapeutics SA – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 30, 2018: Bone Therapeutics announces H1 results for 2018 27
Apr 25, 2018: Bone Therapeutics Announces Full Year 2017 Financial Results 28
Nov 09, 2017: Bone Therapeutics: Business Update for Third Quarter 2017 29
Aug 31, 2017: Bone Therapeutics Announces H1 Results for 2017 30
May 11, 2017: Bone Therapeutics Business Update for First Quarter 2017 32
Mar 16, 2017: Bone Therapeutics Reports Full Year 2016 Results 33
Jan 17, 2017: Bone Therapeutics Provides Business Update for Q4 2016 34
Corporate Communications 36
Jun 14, 2018: Bone Therapeutics announces results of Annual General Meeting 36
Apr 26, 2018: Bone Therapeutics Appoints Claudia D’Augusta As Non-Executive Director 37
Feb 20, 2018: Bone Therapeutics strengthens Board with the appointment of Jean Stephenne as Chairman 38
Aug 31, 2017: Bone Therapeutics Appoints Jean-Luc Vandebroek as Chief Financial Officer 39
Jul 03, 2017: Bone Therapeutics Strengthens Board of Directors 40
May 29, 2017: Bone Therapeutics: Strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors 42
Mar 06, 2017: Bone Therapeutics Strengthens Clinical Development Leadership with Appointment of Dr. Miguel Forte as Chief Medical Officer 43
Other Significant Developments 44
Jan 23, 2018: Bone Therapeutics provides business outlook and announces its financial calendar for 2018 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bone Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bone Therapeutics SA, Deals By Therapy Area, 2012 to YTD 2018 9
Bone Therapeutics SA, Medical Devices Deals, 2012 to YTD 2018 10
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bone Therapeutics Raises US$8 Million In Series D Financing Round 12
Bone Therapeutics to Enter into Agreement with Cellthera Pharm 13
Bone Therapeutics Extends Agreement with Kasios 14
Asahi Kasei Enters into Licensing Agreement with Bone Therapeutics 15
Bone Therapeutics Enters into Licensing Agreement with Enrico Bastianelli 16
Enrico Bastianelli Enters into Licensing Agreement with Bone Therapeutics 17
Bone Therapeutics Enters into Licensing Agreement with Enrico Bastianelli for BONE-011 18
Bone Therapeutics Withdraws Private Placement of Shares 19
Bone Therapeutics Raises USD38 Million in IPO 21
Bone Therapeutics Raises USD24.1 Million in Private Placement of Bonds 23
Bone Therapeutics SA, Key Competitors 24
Bone Therapeutics SA, Key Employees 25
Bone Therapeutics SA, Subsidiaries 26

List of Figures
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bone Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bone Therapeutics SA, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Bone Therapeutics SA (BOTHE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Woodside Petroleum Limited:企業の戦略・SWOT・財務分析
    Woodside Petroleum Limited - Strategy, SWOT and Corporate Finance Report Summary Woodside Petroleum Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Broadspectrum (Australia) Pty Ltd:企業の戦略的SWOT分析
    Broadspectrum (Australia) Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Santen Pharmaceutical Co Ltd (4536):医療機器:M&Aディール及び事業提携情報
    Summary Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacture and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for bacterial conjunctivitis, glaucoma, dry eye, Inflammation and others; OTC …
  • Redrow Plc:企業の戦略・SWOT・財務情報
    Redrow Plc - Strategy, SWOT and Corporate Finance Report Summary Redrow Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Pulmatrix Inc (PULM):企業の財務・戦略的SWOT分析
    Summary Pulmatrix Inc (Pulmatrix), formerly Ruthigen Inc is a clinical stage biopharmaceutical company that discovers and develops inhaled therapeutic products intended for prevention and treatment of respiratory diseases and infections. The company develops its pipeline products using its proprieta …
  • Orly International, Inc.:企業の戦略・SWOT・財務分析
    Orly International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Orly International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • ChanTest Corp-製薬・医療分野:企業M&A・提携分析
    Summary ChanTest Corp (ChanTest), a subsidiary of Charles River Laboratories International Inc is a contract research organization that discovers and develops drugs in ion channel and GPCR biology fields. The organization's ion channel products include cell lines and antibodies. Its other products c …
  • LGT Bank Ltd.:企業の戦略・SWOT・財務分析
    LGT Bank Ltd. - Strategy, SWOT and Corporate Finance Report Summary LGT Bank Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Dolby Laboratories Inc (DLB):企業の財務・戦略的SWOT分析
    Dolby Laboratories Inc (DLB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Westar Energy Inc (WR):企業の財務・戦略的SWOT分析
    Westar Energy Inc (WR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Symic Biomedical Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Symic Biomedical Inc (Symic Biomedical) is a biopharmaceutical company that develops new therapeutics focused on matrix biology. The company’s pipeline products include SB-030 and SB-061. Its SB-030 is a clinical candidate used for the prevention of peripheral vascular diseases or vein graft …
  • Surface Oncology Inc-製薬・医療分野:企業M&A・提携分析
    Summary Surface Oncology Inc (Surface Oncology) is a biopharmaceutical company that develops novel cancer immunotherapies for the treatment of cancer. The company develops treatments in which the immune system can be harnessed to fight cancer. It conducts pre-clinical study through new approaches to …
  • ABITEC Corp:企業の戦略的SWOT分析
    ABITEC Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Hydro-Quebec:電力:M&Aディール及び事業提携情報
    Summary Hydro-Quebec is a government-owned energy utility that generates, transmits and distributes electricity. The company specializes in renewable energy generation, using hydro sources and supports the development of electricity using other technologies such as wind energy and biomass. It genera …
  • OncoTherapy Science Inc (4564)-医療機器分野:企業M&A・提携分析
    Summary OncoTherapy Science Inc (OncoTherapy) is a biotechnology company that discovers and develops antibody drugs. The company offers products under clinical development and anti-cancer medicines. It provides technology platforms that include laser micro-beam microdissection, cDNA microarray and i …
  • Futuren (FTRN):電力:M&Aディール及び事業提携情報
    Summary Futuren, previously Theolia SA, is a wind energy producer that prospects, develops, constructs, installs and operates wind power projects. It specializes in designing and building onshore wind plants. Futuren conducts these operations for its own account as well as for third parties. The com …
  • MallInckrodt Plc (MNK):製薬・医療:M&Aディール及び事業提携情報
    Summary Mallinckrodt Plc (Mallinckrodt) is develops, produces, commercializes, and distributes specialty pharmaceutical therapies and products. The company offers both branded and specialty generics for autoimmune and rare diseases in the specialty therapeutic areas of rheumatology, nephrology, neur …
  • Traverse Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Traverse Biosciences Inc (Traverse Biosciences) is an privately held bioscience company that commercializes drug candidates for the treatment of inflammatory diseases and age-related conditions affecting humans and companion animals. The company provides lead candidate TRB-N0224 which is dev …
  • Lam Research Corp (LRCX):企業の財務・戦略的SWOT分析
    Lam Research Corp (LRCX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Aerovironment Inc
    Aerovironment Inc - Strategy, SWOT and Corporate Finance Report Summary Aerovironment Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆